Genetic Marker

Biobank data suggest targeted polygenic risk score testing in younger adults with borderline or intermediate clinical risk may be a useful strategy for determining who will benefit most from initiating statin therapy, researchers reported.

Cardiomyopathy and HF diagnosis were more common among individuals with certain pathogenic variants compared with those without; however, prevalence was low, between 1% and 3% overall, researchers reported.

Results of a genome-wide association study identified a significant total genetic risk associated with adhesive capsulitis that was similar to the risks associated with hypothyroidism and diabetes.

New research has linked the incidence of unexplained hepatitis in pediatric patients to a pair of viruses — adenovirus type F41 and adeno-associated virus 2 — as well as potential markers of genetic mutation.

In this video, Thomas Waddington, MD, assistant clinical professor in the department of medicine, division of pulmonary and critical care medicine at City of Hope National Medical Center, speaks with Healio about what pulmonologists should know about lung cancer mutations.

Lipoprotein(a) may have a causal role in incident atrial fibrillation risk, independent of its effect on atherosclerotic CVD, according to an analysis of U.K. Biobank data.

Adults with type 2 diabetes and a higher BMI may have an increased risk for diabetic kidney disease, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.

Healthy adults with the highest sensitivity to glucocorticoids have a proteomic profile suggesting a greater capability for responding to stressful stimuli compared with those with lowest sensitivity, according to study data.

People at high genetic risk are more likely to develop type 2 diabetes at some point in their lifetime, but maintaining normal weight may mitigate the increased risk, according to a study published in Diabetic Medicine.

In February, ASCO named molecular profiling driving progress in gastrointestinal cancers as its “Advance of the Year.” According to the American Cancer Society, taken collectively, gastrointestinal cancers have the highest incidence in the U.S. and, after lung cancer, are the second leading cause of cancer-related death. Identifying smaller subsets of patients based on tumor-specific and tumor-agnostic alterations provides insight as to who will benefit from personalized therapies. These subsets ultimately end up being substantial in size and, thus, universal testing should indeed be standard of care for all patients with metastatic gastrointestinal cancer.